KINESCIENCES

KINE SCIENCES is a company that develops ultra-small peptide innovative medicines based on functional immunomics. We discovered the function of a novel cytokine ERDR1 for the first time in the world and since we have been developing drug candidates of ultra-small peptide with private and public funding including the one from Korea Drug Development Fund for consecutive four years. The diseases we aim to treat are chronic immune diseases such as rheumatoid arthritis, inflammatory bowel diseases, atopic dermatitis, psoriasis, cancer, Alzheimer’s disease, and many rare immune diseases. Though we live in an era when we see more research on life sciences and more drugs on the market than any other era of human history, we humans have yet to find cures for these chronic immune diseases by seeing occurrence of resistance or relapse which make lifelong treatment of expensive medicines inevitable for patients. These diseases put a great burden not only on patients themselves but their families and the society as a whole. KINE SCIENCES is committed to treating chronic immune diseases, making lives of patients and their families better, and ultimately improving well-being of humanity by developing safer, more economical and more convenient medicines of ultra small peptides. Please give us encouragement and support for our daunting journey.